Hereditary Angioedema Market to Witness Upsurge in Growth During the Forecast Period 2030, Examine DelveInsight | Key Companies – CSL Behring, Takeda, Shire, Ionis Pharma, KalVista, and Others

 Breaking News
  • No posts were found

Hereditary Angioedema Market to Witness Upsurge in Growth During the Forecast Period 2030, Examine DelveInsight | Key Companies – CSL Behring, Takeda, Shire, Ionis Pharma, KalVista, and Others

December 20
17:06 2021
Hereditary Angioedema Market to Witness Upsurge in Growth During the Forecast Period 2030, Examine DelveInsight | Key Companies - CSL Behring, Takeda, Shire, Ionis Pharma, KalVista, and Others
Delveinsight Business Research LLP
DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hereditary Angioedema Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Hereditary Angioedema market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hereditary Angioedema: An Overview

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx

HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.

Hereditary Angioedema Market Key Facts

  • The total diagnosed prevalent population of Hereditary Angioedema (HAE) in 7MM countries was estimated to be 14,435 cases in 2017.

  • Among the European countries, France had the highest Hereditary Angioedema prevalent population of 1,346 cases, followed by the UK which had a prevalent population of 1,301 in 2017.

  • Spain had the lowest Hereditary Angioedema prevalent population among the EU5 countries with 537 cases in 2017.

  • The Hereditary Angioedema prevalent cases in Japan were found to be 2,534.

  • Hereditary Angioedema in the US has been observed with the maximum number of diagnosed cases in the age-group 17 to below 65 years, followed by those who belong to the age-group 12 to less than 17 years.

  • The main sites of involvement in Hereditary Angioedema (HAE) patients were the skin of the face and limb, oropharynx or larynx, and gastrointestinal (GI), and respiratory tract.

  • According to DelveInsight’s analysis, Hereditary Angioedema is more prominent in females in comparison to males.

Hereditary Angioedema Market 

Hereditary Angioedema Market size was found to be USD 1,987 million in 2020 in the 7MM, which is expected to increase during the forecast period. As per the DelveInsight, the current understanding of Hereditary Angioedema has greatly improved in recent decades, leading to growing awareness, improved management, and better outcomes.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hereditary Angioedema market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Hereditary Angioedema market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Hereditary Angioedema Market Drivers

  • Rising Prevalence

  • Introduction of Oral Therapy

  • Increase in R&D

Get the PDF Sample of the Report:- Hereditary Angioedema Therapeutics Market

Hereditary Angioedema Epidemiology

The epidemiology section covers insights about the historical and current Hereditary Angioedema patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Hereditary Angioedema Epidemiology Segmentation

  • Total Diagnosed Prevalent cases of Hereditary Angioedema

  • Gender-specific cases of Hereditary Angioedema

  • Site-specific cases of Hereditary Angioedema

  • Type-specific cases of Hereditary Angioedema

  • Age-specific cases of Hereditary Angioedema

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched in the market during the study period. The analysis covers Hereditary Angioedema market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Hereditary Angioedema Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Hereditary Angioedema Therapeutics Analysis

The landscape of therapeutic options for patients with Hereditary Angioedema has changed dramatically in the last two decades. Ongoing research promises even greater change in the foreseeable future. Given the economic and psychosocial burdens for patients living with angioedema, effective therapies with novel mechanisms will offer more choices for patients and physicians, as well as provide greater flexibility in routes of administration.

Companies are focusing on executing a successful launch that meets the urgent demand for a once-daily oral therapy that will allow Hereditary Angioedema patients to live a more normal life. An orally delivered, small molecule offers the opportunity to improve treatment for the disease by making it more convenient for patients to take therapies. 

Some of the key companies in the Hereditary Angioedema Market include:

  • CSL Behring

  • Takeda

  • Shire

  • Pharming Group

  • BioCryst Pharmaceuticals

  • Ionis Pharmaceuticals

  • KalVista Pharmaceuticals

And many others

Hereditary Angioedema Therapies covered in the report includes:

  • KVD900 

  • CSL312 

  • Takhzyro

  • Firazyr

  • Ruconest

  • BCX7353

  • Berinert

  • Haegarda

  • Kalbitor

  • Cinryze

  • IONIS-PKK-LRx 

And many more

Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/hereditary-angioedema-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Hereditary Angioedema Competitive Intelligence Analysis

4. Hereditary Angioedema Market Overview at a Glance

5. Hereditary Angioedema Disease Background and Overview

6. Hereditary Angioedema Patient Journey

7. Hereditary Angioedema Epidemiology and Patient Population

8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices

9. Hereditary Angioedema Unmet Needs

10. Key Endpoints of Hereditary Angioedema Treatment

11. Hereditary Angioedema Marketed Products

12. Hereditary Angioedema Emerging Therapies

13. Hereditary Angioedema Seven Major Market Analysis

14. Attribute Analysis

15. Hereditary Angioedema Market Outlook (7 major markets)

16. Hereditary Angioedema Access and Reimbursement Overview

17. KOL Views on the Hereditary Angioedema Market.

18. Hereditary Angioedema Market Drivers

19. Hereditary Angioedema Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/hereditary-angioedema-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/